




The relative strengths and weaknesses of Achillion Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Achillion Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 169% points. The greatest weakness of Achillion Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is 330%, being 110% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	67,867
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,136
Liabilities, Non-Current	347
Other Assets	12,416
Other Compr. Net Income	39
Other Expenses	68
Other Liabilities	0
Other Net Income	234
Other Revenues	2,607
Property and Equipment	1,247
Research and Development	38,999
Selling, General and Administrative Expense	10,901

Output Variable	Value in 1000 USD
Assets	81,530
Liabilities	9,483
Expenses	49,968
Revenues	2,607
Stockholders Equity	72,047
Net Income	-47,127
Comprehensive Net Income	-47,108
BaseVar	71,930
ECR before Limited Liability	242%
Economic Capital Ratio	330%